These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

434 related items for PubMed ID: 18303486

  • 1. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.
    Ferreira JJ, Almeida L, Cunha L, Ticmeanu M, Rosa MM, Januário C, Mitu CE, Coelho M, Correia-Guedes L, Morgadinho A, Nunes T, Wright LC, Falcão A, Sampaio C, Soares-da-Silva P.
    Clin Neuropharmacol; 2008; 31(1):2-18. PubMed ID: 18303486
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
    Nunes T, Machado R, Rocha JF, Fernandes-Lopes C, Costa R, Torrão L, Loureiro AI, Falcão A, Vaz-da-Silva M, Wright L, Almeida L, Soares-da-Silva P.
    Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
    [Abstract] [Full Text] [Related]

  • 3. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J, Kaakkola S, Ahtila S, Tuomainen P, Teräväinen H.
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel catechol-o-methyltransferase inhibitor, and controlled-release levodopa/carbidopa 200 mg/50 mg : randomized, double-blind, placebo-controlled, crossover study in healthy subjects.
    Vaz-da-Silva M, Loureiro AI, Nunes T, Lopes C, Rocha J, Machado R, Costa R, Torrão L, Falcão A, Wright L, Almeida L, Soares-da-Silva P.
    Drugs R D; 2008 Jul; 9(6):435-46. PubMed ID: 18989992
    [Abstract] [Full Text] [Related]

  • 5. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.
    Corvol JC, Bonnet C, Charbonnier-Beaupel F, Bonnet AM, Fiévet MH, Bellanger A, Roze E, Meliksetyan G, Ben Djebara M, Hartmann A, Lacomblez L, Vrignaud C, Zahr N, Agid Y, Costentin J, Hulot JS, Vidailhet M.
    Ann Neurol; 2011 Jan; 69(1):111-8. PubMed ID: 21280081
    [Abstract] [Full Text] [Related]

  • 6. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.
    Rocha JF, Falcão A, Santos A, Pinto R, Lopes N, Nunes T, Wright LC, Vaz-da-Silva M, Soares-da-Silva P.
    Eur J Clin Pharmacol; 2014 Sep; 70(9):1059-71. PubMed ID: 24925090
    [Abstract] [Full Text] [Related]

  • 7. Chronopharmacology of nebicapone, a new catechol-O-methyltransferase inhibitor.
    Almeida L, Loureiro AI, Vaz-da-Silva M, Torrão L, Maia J, Fernandes-Lopes C, Falcão A, Igreja B, Wright L, Soares-da-Silva P.
    Curr Med Res Opin; 2010 May; 26(5):1097-108. PubMed ID: 20225994
    [Abstract] [Full Text] [Related]

  • 8. The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease.
    Heikkinen H, Nutt JG, LeWitt PA, Koller WC, Gordin A.
    Clin Neuropharmacol; 2001 May; 24(3):150-7. PubMed ID: 11391126
    [Abstract] [Full Text] [Related]

  • 9. [Inhibition of the COMPT with entacapone in the treatment of motor fluctuations in Parkinson disease].
    Kulisevsky J.
    Neurologia; 1999 May; 14(7):349-58. PubMed ID: 10570622
    [Abstract] [Full Text] [Related]

  • 10. Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease.
    Müller T, Kolf K, Ander L, Woitalla D, Muhlack S.
    Clin Neuropharmacol; 2008 May; 31(3):134-40. PubMed ID: 18520980
    [Abstract] [Full Text] [Related]

  • 11. A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's disease.
    Ferreira JJ, Rascol O, Poewe W, Sampaio C, Rocha JF, Nunes T, Almeida L, Soares-da-Silva P, BIA-3202-202 Study Investigators.
    CNS Neurosci Ther; 2010 Dec; 16(6):337-47. PubMed ID: 20653695
    [Abstract] [Full Text] [Related]

  • 12. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease.
    Ferreira JJ, Rocha JF, Falcão A, Santos A, Pinto R, Nunes T, Soares-da-Silva P.
    Eur J Neurol; 2015 May; 22(5):815-25, e56. PubMed ID: 25649051
    [Abstract] [Full Text] [Related]

  • 13. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
    Olanow CW, Kieburtz K, Stern M, Watts R, Langston JW, Guarnieri M, Hubble J, US01 Study Team.
    Arch Neurol; 2004 Oct; 61(10):1563-8. PubMed ID: 15477510
    [Abstract] [Full Text] [Related]

  • 14. Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease.
    Rocha JF, Ferreira JJ, Falcão A, Santos A, Pinto R, Nunes T, Almeida L, Soares-da-Silva P.
    Clin Pharmacol Drug Dev; 2016 May; 5(3):232-40. PubMed ID: 27163503
    [Abstract] [Full Text] [Related]

  • 15. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly.
    Jorga KM, Sedek G, Fotteler B, Zürcher G, Nielsen T, Aitken JW.
    Clin Pharmacol Ther; 1997 Sep; 62(3):300-10. PubMed ID: 9333106
    [Abstract] [Full Text] [Related]

  • 16. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.
    Piccini P, Brooks DJ, Korpela K, Pavese N, Karlsson M, Gordin A.
    J Neurol Neurosurg Psychiatry; 2000 May; 68(5):589-94. PubMed ID: 10766888
    [Abstract] [Full Text] [Related]

  • 17. Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
    Ishihara A, Miyachi T, Nakamura T, Ohtsuki T, Kimura Y, Kihira K, Yamawaki T, Matsumoto M.
    Hiroshima J Med Sci; 2011 Sep; 60(3):57-62. PubMed ID: 22053701
    [Abstract] [Full Text] [Related]

  • 18. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers.
    Illi A, Sundberg S, Ojala-Karlsson P, Scheinin M, Gordin A.
    Clin Pharmacol Ther; 1996 Apr; 59(4):450-7. PubMed ID: 8612391
    [Abstract] [Full Text] [Related]

  • 19. Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.
    Najib J.
    Clin Ther; 2001 Jun; 23(6):802-32; discussion 771. PubMed ID: 11440283
    [Abstract] [Full Text] [Related]

  • 20. Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR.
    Paija O, Laine K, Kultalahti ER, Leinonen M, Huupponen R, Gordin A, Reinikainen K.
    Clin Neuropharmacol; 2005 Jun; 28(3):115-9. PubMed ID: 15965309
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.